Showing results (71-80 of 167) with videos related to

Sort By:
Pageof 17
JNCI Cancer Spectrum|June 2, 2025
INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner's curseYu Yang Soon, Katrin Sjoquist, Ian C Marschner, et al.
British Journal of Cancer|March 10, 2017
Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancerHui-Ming Lin, Kate L Mahon, Calan Spielman, et al.
Breast (Edinburgh, Scotland)|July 2, 2023
10-Year axillary recurrence in the RACS SNAC1 randomised trial of sentinel lymph node-based management versus routine axillary lymph node dissectionIan Campbell, Neil Wetzig, Owen Ung, et al.
Psycho-Oncology|July 21, 2006
Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancerVlatka M Duric, Phyllis N Butow, Louise Sharpe, et al.
Therapeutic Advances in Medical Oncology|December 18, 2024
Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapyRhiannon Mellor, Luke Ardolino, Tahlia Scheinberg, et al.
Basic and Clinical Andrology|September 2, 2024
Association between low total serum testosterone and body mass index in Australian survivors of testicular cancer: a retrospective analysisGrace Y Kim, Ciara Conduit, Sophie O'Haire, et al.
JNCI Cancer Spectrum|June 23, 2021
Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon CancerPrunella Blinman, Andrew Martin, Michael Jefford, et al.
Patient Education and Counseling|April 25, 2008
Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancerVlatka M Duric, Phyllis N Butow, Louise Sharpe, et al.
The Oncologist|October 11, 2013
Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit studyKatrin M Sjoquist, Michael L Friedlander, Rachel L O'Connell, et al.
International Journal of Radiation Oncology, Biology, Physics|December 21, 2025
A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiotherapy (SABR) in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD)Gargi Kothari, Kenneth J O'Byrne, Chris Brown, et al.
Pageof 17